Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2006-06-06
2006-06-06
Jones, Dameron L. (Department: 1618)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C424S001110, C424S001650
Reexamination Certificate
active
07056491
ABSTRACT:
A method of sensitizing tumor cells to radiation thereapy, chemotherapy and immunomodulatory thereapy, comprising the step of exposing the tumor cell to an effective amount of at least one monoterpene or sesquiterpene and treating the tumor cell is disclosed.
REFERENCES:
patent: 5587402 (1996-12-01), Gould et al.
patent: 5602184 (1997-02-01), Myers et al.
patent: 2002/0054850 (2002-05-01), Gould et al.
patent: 2003/0054052 (2003-03-01), Haridas et al.
patent: 2003/0125373 (2003-07-01), Nakshatri et al.
patent: WO 94/20080 (1994-09-01), None
Rajesh, D. et al., Perillyl Alcohol as a Radiosensitizer in Malignant Gliomas, abstract of presentation made at SNO Meeting (11/12/2000), Chicago.
Boesen-De-Cock, Jeanine G.R., et. al., Common Regulation of Apoptosis Signaling Induced by CD95 and the DNA-damaging Stimuli Etoposide and -Radiation Downstream from Caspase-8 Activation, Journal of Bio. Chem., 274:20, Issue of May 14, 14255-14261, 1999.
Duan, Lian et al., Sensitization of Human Malignant Glioma Cell Lines to Tumor Necrosis Factor-Induced Apoptosis by Cisplatin, Journal of Neuro-Oncology 52:23-36, 2001.
Fulda, Simone et al., The CD95 (APO-1/Fas) System Mediates Drug-Induced Apoptosis in Neuroblastoma Cells, Cancer Research 57, 3823-3829, Sep. 1, 1997.
Fulda, Simone et al., Activation of the CD95 (APO-1/Fas) Pathway in Drug- and-Irradiation-induced Apoptosis of Brain Tumor Cells, Cell Death and Differentiation (1998) 5, 884-893.
Green, Douglas R., Apoptotic Pathways: The Roads to Ruin, Cell 94:695-698, Sep. 18, 1998.
Herr, Ingrid et al., Activation of CD95 (APO-1/Fas) Signaling by Ceramide Mediates Cancer Therapy-Induced Apoptosis, EMBO Journal 16:20, 6200-6208, 1997.
Houghton, Janet A. et al., The Fas Signaling Pathway is Functional in Colon Carcinoma Cells and Induces Apoptosis, Clin. Cancer Res. 3:2205-2209, Dec. 1997.
Kimura, Kotohiko et al., Tumor Necrosis Factor- and Fas Activate Complementary Fas-associated Death domain-dependent Pathways that Enhance Apoptosis Induced by-Irradiation, Journ. Biol. Chem., 275:12, Iss. Of Mar. 24, 8610-8617, 2000.
Li, Jie-Hui et al., The Regulation of CD95 Ligand Expression and Function in CTL, American Association of Immunologists 3943-3949, 1998.
Micheau, Olivier et al., Sensitization of Cancer Cells Treated with Cytotoxic Drugs to Fas-Mediated Cytotoxicity, J. Nat. Cancer Inst. 89:11, Jun. 4, 1997.
Mizutani, Youichi et al., Doxorubicin Sensitizes Human Bladder Carcinoma Cells to Fas-Mediated Cytotoxicity, Cancer 79:6, 1180-1189, Mar. 15, 1997.
Mueller, Martina et al., p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs, J. Exp. Med. 188:11, Dec. 7, 1998, 2033-2045.
Nagata, Shigekazu, Fas Ligand-Induced Apoptosis, Annu. Rev. Genet. 1999, 33:29-55.
O'Connor, Liam et al., CD95 (Fas/APO-1) and p53 Signal Apoptosis Independently in Diverse Cell Types, Cancer Res. 60, 1217-1220, Mar. 1, 2000.
Pinkoski, M.J. and Green, D.R., Fas Ligand, Death Gene, Cell Death and Differentiation (1999) 6, 1174-1181.
Rokhlin, Oskar W., et al., Fas-Mediated Apoptosis in Human Prostatic Carcinoma Cell Lines Occurs Via Activation of Caspase-8 and Caspase-7, Cancer Research 58, 5870-5875, Dec. 15, 1998.
Roth, W. et al., Taxol-Mediatied Augmentation of CD95 Ligand-Induced Apoptosis of Human Malignant Glioma Cells: Association with bcl-2 Phosphorylation but Neither Activation of p53 nor G /M Cell Cycle Arrest, British J. of Cancer (1998) 77(3):404-411.
Roth, Wilfried et al., Interferon- Enhances CD95L-Induced Apoptosis of Human Malignant Glioma Cells, J. of Neuroimmun. 87 (1998) 121-129.
Weller, Michael, CD95 Ligand: Lethal Weapon Against Malignant Glioma? Brain Path. 8:285-293 (1998).
Wu, Xiu-Xian, Enhancement of Fas-Mediated Apoptosis in Renal Cell Carcinoma Cells in Adriamycin, Cancer Res. 60, 2912-2918, Jun. 1, 2000.
Yount, Garret L., Fas (APO-1/CD95) Signaling Pathway is Intact in Radioresistant Human Glioma Cells, Cancer Res., 59, 1362-1365, Mar. 15, 1999.
Zagury, Daniel, Toward a New Generation of Vaccines: the Anti-Cytokine Therapeutic Vaccines, PNAS 98:14 8024-8029, Jul. 3, 2001.
M. Mehta, et al., “Brain Tumor Committee,” Int. J. Radiation Oncology Biol. Phys. 51(3):11-18, 2001.
A. C. Miller and D. Samid, “Tumor Radiosensitization Based on the Use of Inhibitors of the Mevalonate Pathway of Cholesterol Synthesis,” Eicosanoids and Other Bioactive Lipids in Cancer Inflammation and Radiation Injury 2, Edited by K.V. Honn et al, 1997, pp. 825-830.
Broitman SA, et al., “Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic ‘metastases’ in vivo,” Adv. Exp. Med. Biol. 401:111-130, 1996.
Chen Y and Hu D, “Effects of POH in combination with ST1571 on the proliferation and apoptosis of K562 cells,” J. Huazhon Univ. Sci. Technolog. Med. Sci. 24(1):41-44, 2004.
Hyer ML, et al., “Synthetic triterpenoids cooperates with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells,” Cancer Res. 6541), 4799-4808, 2005.
Keane MM, et al., “Chemotherapy augments TRAIL-induced apoptosis in breast cell lines,” Cancer Res. 59(3):734-741, 1999.
Mo H and Elson CE, “Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention,” Exp. Biol. Med. 229:567-585, 2004.
Rajesh D, et al., “Perillyl alcohol as a radio-/chemosensitizer in malignant glioma,” J. Biol. Chem. 278(38):35968-35978, 2003.
Shi B, et al., “The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo,” Cancer Chemother. Pharmacol 46:387-393. 2000.
Vigushin DM, et al., “Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee,” Cancer Chemother Pharmacol 42(2:111-117 1998.
Yu D, “Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers,” 28(Suppl. 16):12-17, 2001.
Zhang S, et al., “Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms,” Curr. Med. Chem. Anti-Canc. Agents 5(3):239, 2005.
International Agency for Research on Cancer IARC)—Summaries & Evaluations, Lumber and Sawmill Industries (Including Logging) (Group 3) Suppl. 7:383, 1987.
Gould Michael N.
Howard Steven P.
Rajesh Deepika
Jones Dameron L.
Quarles & Brady LLP
Wisconsin Alumni Research Foundation
LandOfFree
Monoterpenes and sesquiterpenes as chemotherapeutic and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoterpenes and sesquiterpenes as chemotherapeutic and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoterpenes and sesquiterpenes as chemotherapeutic and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3678261